Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Many Physicians Prescribe Medium/High-Dose Pill: User Education Needed
August 6, 2001
- BUSINESS NEWS IN BRIEF
August 6, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
August 6, 2001
- Yoshitomi to Focus Only on Psychiatric Field
August 6, 2001
- Dr Kawakita Urges Medical Facilities to Improve Quality of Services: Seminar
August 6, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
August 6, 2001
- Kenporen to Cooperate with Nikkeiren, Rengo in Healthcare Reform
August 6, 2001
- CRO Business Expanding Rapidly: Association Report
August 6, 2001
- Chamber Councils Selection System to Be Started in Medical Malpractice Suits
August 6, 2001
- Kasamatsu Meiki, Hokuho Iyaku to Merge on Oct. 1
August 6, 2001
- WORLD NEW IN BRIEF
August 6, 2001
- Int'l Licensing Symposium to Be Held in Tokyo in September
August 6, 2001
- Gap between Boots and Mitsubishi Strategies Seen in Close of 4 Stores
August 6, 2001
- Development of Kissei's Rizaben Discontinued by GSK
August 6, 2001
- Sun Drug-Kawachi Yakuhin Alliance Likely to Be Successful: Security Analyst
August 6, 2001
- 3 Groups to Study How to Improve Supply of Drug Information
August 6, 2001
- BULLETIN
August 6, 2001
- BULLETIN
August 6, 2001
- Council Recommends Abolition of \205 Rule, Review of NHI Pricing Rule
August 6, 2001
- DIAGNOSTIC NEWS IN BRIEF
August 6, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…